Ver­sant-backed Ven­tus scores $100M round to tur­bocharge its dual-plat­form play at 'drug­ging the un­drug­gable'

If one thing is true in bio­phar­ma ven­ture cap­i­tal, it’s that in­vestors love a plat­form play. Now, a biotech with per­son­nel split across the US and Cana­da is rolling in a rush of in­vestor cash to ad­vance its pur­suit of “drug­ging the un­drug­gable” with a dual plat­form it be­lieves could help build a bet­ter small mol­e­cule.

Waltham, MA- and Mon­tre­al-based Ven­tus has snared a $100 mil­lion Se­ries B to ad­vance its five com­pounds, in­clud­ing an NL­RP3 in­flam­ma­some small mol­e­cule in­hibitor the biotech thinks could of­fer a much greater de­gree of chem­i­cal di­ver­si­ty than its ri­vals, the com­pa­ny said Thurs­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER